Lisdexamfetamine mesilate
Brand names: Elvanse
Lisdexamfetamine mesilate is a long-acting prodrug stimulant (converted to dexamfetamine) used for attention deficit hyperactivity disorder, typically as part of a comprehensive treatment programme.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
After absorption it is metabolised to active dexamfetamine, which increases synaptic dopamine and noradrenaline by promoting release and blocking reuptake, improving attention and reducing impulsivity.
Prescribing in practice
- As a stimulant it can raise heart rate and blood pressure and is contraindicated in significant cardiovascular disease, so assess cardiovascular history and check blood pressure, heart rate and growth before and during treatment.
- It is a controlled drug with potential for dependence and misuse and should not be used where there is a history of stimulant or substance misuse without specialist judgement.
- Monitor for psychiatric effects such as new or worsening anxiety, agitation, tics or psychotic symptoms, and for appetite suppression and growth retardation in children.
Monitoring
Monitor heart rate, blood pressure, weight, height and appetite, mental state and for signs of dependence throughout treatment.
Counselling the patient
- Take in the morning to avoid disturbed sleep.
- Report chest pain, palpitations, fainting or new mood or behavioural changes.
- Reduced appetite is common; keep regular meals and attend growth and monitoring checks.
Evidence & guidelines
NICE ADHD guidance includes lisdexamfetamine among recommended stimulant options, with structured cardiovascular and growth monitoring.
Reference: NICE NG87; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185